Flexion Therapeutics (NASDAQ: FLXN) reported top-line results from the first of two pivotal clinical trials of its lead drug candidate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE